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The primary structure of murine apolipoprotein A-II (apo A-II) has been determined. Apo A-II consists 
of a single polypeptide chain of 78 amino acid residues, of which the amino-terminus is pyrrolidone car- 
boxylic acid. Except for residues 5 and 38, the amino acid sequence is identical to that of murine senile 
amyloid protein (ASSAM), which has a common antigenicity with apo A-II. Substitution of glutamine 
(ASsAM) for proline (apo A-II) at position 5 is distinct and may possibly be related to murine senile amyloid- 
ogenesis. 
Primary structure Apolipoprotein A-II Murine senile amyloid protein 
Proiine-glutamine substitution 
1. INTRODUCTION 
Apolipoproteins are important structural consti- 
tuents of lipoprotein particles and are involved in 
lipoprotein synthesis, secretion, processing and 
catabolism [l]. Apolipoprotein (apo) A-II is the 
second most abundant protein _constituent of 
human and murine high density lipoproteins [2]. 
Although both apo A-II and apo A-l may be 
potential predictors of cardiovascular disease 
[3,4], the physiological role of apo A-II in lipopro- 
tein metabolism has not been clearly defined. 
Human apo A-II is a dimeric protein composed 
of two identical peptide chains of 77 amino acid 
residues. The peptide chains have pyrrolidone car- 
boxylic acid (PCA) at the amino-termini and are 
linked by a disulfide bridge at Cys 6 [5]. In mice 
and other species, apo A-II is a monomer [6]. 
+ To whom correspondence should be addressed 
Abbreviations: CNBr, cyanogen bromide; SAM, 
senescence accelerated mouse; HDL, high density 
lipoprotein; HPLC, high-performance liquid chro- 
matography; AP, Achromobacter protease I 
The mouse is a most useful animal model for 
studying normal and pathological processes and 
genetic variations in lipoprotein metabolism. To 
date, the amino acid sequence of only a few murine 
apolipoproteins have been determined. We recent- 
ly determined the primary structure of murine 
senile amyloid fibril protein (ASSAM) from the 
murine model for accelerated senescence [7] and 
found that apo SASSAM, which is a serum precur- 
sor of ASSAM, is murine apo A-II [7,8]. 
Now we report the purification of apo A-II from 
murine serum and its determined primary struc- 
ture. Sequence comparisons revealed one complete 
and one partial substitution of amino acid residues 
between apo A-II and ASSAM. 
2. MATERIALS AND METHODS 
2.1. Purification of apo A-II 
Murine serum apoproteins in HDL fractions 
(apo HDL) were obtained from 3-month-old male 
ICR mice and apo HDL were fractionated on 
Sephadex G-200, as described [9]. The proteins at 
the third peak were chromatographed on DEAE- 
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celluIose (DE-52) with a linear gradient from 0.01 
to 0.1 M Tris-HCI in 6 M urea at pH 8.2. Two pro- 
teins (apo A-II-l and apo A-11-2) in separate peaks 
reacted with anti-A&M serum and each protein 
was further purified by reverse-phase HPLC on a 
Baker bond wide pore butyl column (0.46 x 25 
cm, C4, 330 A). Elution was performed with a 
linear gradient from 0 to 60%, 2-propanol/ 
acetonitrile (7:3, v/v) in 0.1% trifluoroacetric acid 
(TFA) for 1 h at a flow rate of 1 ml per min. 
Table 1. 
Amino acid composition of apo A-II-l and ASSAM- 1 
Amino acid Apo A-II-l 
(residues/mol) 
ASSAM - la 
2.2. Removal and ~denii~~~at~o~ o~pyrro~~do~e 
~arboxy~ic acid (PCA) 
The amino-terminal PCA was liberated from 
apo A-II-l and apo A-II-2 using calf liver 
pyroglutamyl peptidase (L-pyroglutamyl-peptide 
hydrolase, EC 3.4.19.34, Sigma) and identified as 
described 171. 
2.3. Peptide fragmentation and separation 
Fragmentation of apo A-II-1 or apo A-II-2 with 
AP, Staphylococcus aureus V8 protease (SP) and 
CNBr were performed as reported 171. Peptides 
were fractionated on a reverse-phase C-4 as 
described above. 
Asp 
ThrC 
Se? 
GlU 
Pro 
GlY 
Ala 
‘55 cys 
Vale 
Met 
Ilee 
Leu 
Tyr 
Phe 
Lys 
His 
Trp 
Ar8 
5.4 (5)b 5 
5.7 (6) 6 
7.7 (8) 8 
14.0 (14) 15 
3.7 (4) 3 
3.3 (3) 3 
7.3 (7/8)d 8 
0 (0) 0 
3.6 (4/3)d 3 
2.5 (3) 3 
1.0 (1) 1 
7.2 (7) 7 
3.0 (3) 3 
4.9 (5) 5 
5.6 (6) 6 
1.0 (1) I 
0 (0) 0 
1.1 (1) 1 
Total (78) (78) 
a Data from [7] 
b Numbers in parentheses are based on amino acid se- 
2.4. Amino acid and sequence analysis 
quence (fig.2) 
Amino acid analysis, automated Edman 
degradation and identifiction of PTH amino acids 
by reverse-phase HPLC were carried out as 
described [7]. 
’ Values are those extrapolated to 0 h 
d Due to microheterogeneity at position 38. The ratio of 
Ala to Val at this position is 1:2 based on these 
numerical values 
’ Values for 72 h hydrolyzate 
3. RESULTS AND DISCUSSION 
Apo A-II-l, the major component, and apo A- 
11-2, the minor one, were eluted from a DEAE- 
cellulose column at positions corresponding to apo 
SAS~AM-I and apo SASSAM-& respectively. These 
components have a common antigenicity with 
ASSAM in serum 181. On 8 M urea polyacrylamide 
gel electrophoresis, each of the purified proteins 
gave a single band and apo A-II-2 had a slightly 
greater mobility than apo A-II-I (not shown). 
11-l was incubated with calf liver pyroglutamyl 
peptidase. Subsequently, the first 30 amino acids 
were determined by automated Edman degrada- 
tion. In the N-terminal 30 residues, the sole dif- 
ference between apo A-II-l and ASSAM-~ was 
observed at residue 5: glutamine in ASSAM-~ was 
replaced by proline in apo A-II-l. Pyroglutamic 
acid liberated from apo A-II was identified by 
reverse-phase HPLC and amino acid analysis as 
described [7] (not shown). 
In table 1, the amino acid composition of apo A- Apo A-II-I was digested with AP and the 
II-1 is presented together with that of ASSAM-~. resulting AP peptides were separated by reverse- 
Both proteins possessed the same composition, ex- phase HPLC (fig.1). The amino acid composition 
cept for glutamic acid, proline, alanine and valine. of each peptide was determined and then se- 
Apo A-II-I had no PTH-amino acid at the first cy- quenced. Comparison of the peptide map of apo 
cle of Edman degradation. The second residue A-II-1 with that of ASSAM-I showed critical dif- 
from the N-terminus was exposed when the apo A- ferences in a few peaks. First, peptide API was 
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Fig.1. The elution profile obtained by digestion of apo A-II-1 and AS SAM - 1 with Achromobacter protease I.
eluted at a different position, as expected from the 
finding that apo A-II-l contains Pro instead of Gln 
5 in ASSAM-I. One proline and five glutamic acids 
were consistently determined by amino acid 
analysis of peptide AP 1. Secondly, AP4’ was 
found only in the case of apo A-II-l. The amino 
acid composition was the same as that of AP4, ex- 
cept for alanine and valine. The molar ratio of 
AP4 and AP4’ was 1:2. Sequence analysis revealed 
that AP4’ differs from AP4 only at the residue 
penultimate to the C-terminal lysine. The residue is 
valine in the former peptide and alanine in the lat- 
ter. Thirdly, the elution of AP7 and AP6-7 of apo 
A-II-l was more rapid than that of ASSAM-I. 
However, the same sequences were determined for 
their counterparts of ASSAM-I. While we have no 
exact explanation for the difference in the elution 
behavior of those peptides, the oxidation of 
methionine during peptide isolation has to be con- 
sidered. CNBr cleavage and V8 protease digestion 
were also performed for apo A-II-l and several 
peptides thus formed were used to confirm the 
complete sequence. 
The complete amino acid sequence of murine 
apo A-II-1 is shown in fig.2. Murine apo A-II-1 
consists of a single polypeptide chain of 78 amino 
acid residues with a molecular mass of 8721 Da. 
The amino-terminus is PCA, that is, the same as 
human apo A-II protein. Sequence homology is 
high between murine and human apo A-II. 55% of 
the amino acids in the two proteins are identical 
and 34% of the remaining residues represents con- 
servative substitutions [5]. Like the case of ASSAM, 
the amino acid sequences of two components of 
apo A-II (apo A-II-l and -2) are identical in spite 
of the different electrophoretic mobility. At pre- 
sent we cannot clarify what kind of modification 
occurs in native apo A-11-2, so further studies are 
25 
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1 10 20 
apo A-II-1 <ZADGPDMQSLFTQYFcSMTEYGKDL 4.w 
(--_-_-_-_-_-------- ___________Ap1______--_______________t_- 
~--~~---~~~~---~~~--- SPl __-_________________--____Sp2- 
35 45 
SEIQSQOKAYFEKTHEQLT 
-AP2r,AP3 -P4-eAP5--AP6- 
- 
eAP4' 4 -AP6-7- 
__t*___SP3___-~_______~p4____----~4-Sp~-- _-e-m 
~_______~p4-'_______* 
60 70 
PLVRSAGTSLVNFFSSLMNLEEKPA 
-AP6-4 AP7 ----AP8 
- 
AP6-7 ------ 
---------_____________Sp6 ________________-_____~*~P7-_- 
-CB4 
PAA 
-APSt 
--SP7- c---t Sequenced portion 
-CB4c +---Amino acid analysis only 
Fig.2. Complete amino acid sequence of apo A-II-l showing the positions of peptides for which sequence data (solid 
lines) or composition data (broken lines) were obtained. The arrow (+) represents direct sequencing of the N”- 
deblocked protein. AP, SP, and CB represent peptides obtained Achromobacter protease I, Staphylococcus aureus V8 
protease digestion and CNBr degradation, respectively. 
necessary to elucidate this modification. 
It is remarkable that, at position 5, glutamine in 
ASSAM-~ is substituted for proline in apo A-11-1, 
since the former amino acid is dinstinct from the 
latter, in terms of conformational potency (fig.3). 
The extensive deposition of ASSAM protein which 
occurred extracellularly with advancing age in the 
senescence accelerated prone mice (SAM-P) [lo] 
may relate to this particular amino acid substitu- 
tion. Although a number of mutants of human 
apolipoproteins has been identified [ 1,111, a muta- 
tion in the apo-II molecule has apparently not been 
reported. The Pro+Gln substitution described 
here seems to be the first report of a mutation in 
apo A-II. In the case of human familial amyloid 
polyneuropathy (FAP), several types of amino 
26 
acid substitutions in serum prealbumin molecules 
seem to closely correlate with amyloid fibril forma- 
tion [12-141. Murine apo A-II obtained from ran- 
dom bred ICR mice does have a sequence 
heterogeneity at position 38, but replacement of 
valine for alanine at this position is unlikely to pro- 
duce a significant change in the structure of the 
protein or have an important effect on apo A-II 
metabolism. 
The mouse has been a species rarely used for 
lipoprotein research. Our finding of a remarkable 
variation in apo A-II molecules in this species 
should enhance the usefulness of the mouse as a 
model system for examination of the function of 
apo A-II. The elucidation of this mutation should 
aid in determining the pathogenesis of 
amyloidosis. 
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1 10 
apo A-II-1 <ZADGPDMQSLFT 
AS SAM-’ 0 
CZADGQDMQSLFT 
35 
VEKAKTSEIQSQ 
VEKAKTSEIQSQ 
60 70 
PLVRSAGTSLVN FFSSLMNLEEKPA 
PLVRSAGTSLVN FFSSLMNLEEKPA 
PAA 
PAA 
Fig.3. Comparison of the amino acid sequence between apo A-II-l 
boxed. 
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